Zuniga A - Search Results

1

Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.

Cantarella G, Liniger M, Zuniga A, Schiller JT, Billeter M, Naim HY, Glueck R. Cantarella G, et al. Among authors: zuniga a. Vaccine. 2009 May 26;27(25-26):3385-90. doi: 10.1016/j.vaccine.2009.01.061. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200837 Free PMC article.

2

Attenuated measles virus as a vaccine vector.

Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, Wild P, Viret JF, Glueck R, Billeter MA, Naim HY. Zuniga A, et al. Vaccine. 2007 Apr 20;25(16):2974-83. doi: 10.1016/j.vaccine.2007.01.064. Epub 2007 Feb 2. Vaccine. 2007. PMID: 17303293 Free PMC article.

3

Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.

Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, Wiegand M, Weibel S, Kelvin D, Rota PA, Naim HY. Liniger M, et al. Among authors: zuniga a. Vaccine. 2008 Apr 16;26(17):2164-74. doi: 10.1016/j.vaccine.2008.01.057. Epub 2008 Feb 22. Vaccine. 2008. PMID: 18346823 Free PMC article.

4

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses.

Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, Ilter O, Knuchel M, Naim HY. Liniger M, et al. Among authors: zuniga a. Vaccine. 2009 May 26;27(25-26):3299-305. doi: 10.1016/j.vaccine.2009.01.057. Epub 2009 Feb 5. Vaccine. 2009. PMID: 19200842 Free PMC article.

5

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.

Knuchel MC, Marty RR, Morin TN, Ilter O, Zuniga A, Naim HY. Knuchel MC, et al. Among authors: zuniga a. Hum Vaccin Immunother. 2013 Mar;9(3):599-606. doi: 10.4161/hv.23241. Epub 2013 Jan 16. Hum Vaccin Immunother. 2013. PMID: 23324399 Free PMC article.

6

Use of viral vectors for the development of vaccines.

Liniger M, Zuniga A, Naim HY. Liniger M, et al. Among authors: zuniga a. Expert Rev Vaccines. 2007 Apr;6(2):255-66. doi: 10.1586/14760584.6.2.255. Expert Rev Vaccines. 2007. PMID: 17408374 Review.

7

Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.

Hervé PL, Dhelft V, Zuniga A, Ghasparian A, Rassek O, Yim KC, Donne N, Lambert PH, Benhamou PH, Sampson HA, Mondoulet L. Hervé PL, et al. Among authors: zuniga a. Vaccine. 2021 Jul 22;39(32):4555-4563. doi: 10.1016/j.vaccine.2021.03.081. Epub 2021 Jun 19. Vaccine. 2021. PMID: 34154864 Free article.

8

An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus.

Zuniga A, Rassek O, Vrohlings M, Marrero-Nodarse A, Moehle K, Robinson JA, Ghasparian A. Zuniga A, et al. NPJ Vaccines. 2021 Jun 18;6(1):85. doi: 10.1038/s41541-021-00347-y. NPJ Vaccines. 2021. PMID: 34145291 Free PMC article.

9

Author Correction: An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus.

Zuniga A, Rassek O, Vrohlings M, Marrero-Nodarse A, Moehle K, Robinson JA, Ghasparian A. Zuniga A, et al. NPJ Vaccines. 2021 Aug 27;6(1):111. doi: 10.1038/s41541-021-00375-8. NPJ Vaccines. 2021. PMID: 34453064 Free PMC article. No abstract available.

10

A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A.

Tamborrini M, Geib N, Marrero-Nodarse A, Jud M, Hauser J, Aho C, Lamelas A, Zuniga A, Pluschke G, Ghasparian A, Robinson JA. Tamborrini M, et al. Among authors: zuniga a. Vaccines (Basel). 2015 Oct 16;3(4):850-74. doi: 10.3390/vaccines3040850. Vaccines (Basel). 2015. PMID: 26501327 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

321 results

Search Page